
Evora Biosciences
Société
|
France, Illkirch-Graffenstaden
1
abonnés
Onglets principaux
À propos de votre organisation / profil
Evora Biosciences develops first-in-class anti-inflammatory peptides, with a focus on so-called "un-druggable targets" in multi-billion therapeutic areas.
Its lead API, EVO-003, is the world's first universal TLR-4 inhibitor. A true pipeline-in-a-product asset, EVO-003 has the potential to adress a large array of indications, and already exhibits exciting preclinical data in vitro and in vivo in various models (ARDS, sepsis, chemotherapy-induced ototoxicity, skin inflammation, eye inflammation e.g).
Evora Biosciences aims to start clinical trials in 2026.
Réseau (0)
Il n'y a pas encore d'organisations dans le réseau.